Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of LinkedIn (NYSE: LNKD ) plunged today by as much as 14% after the company reported earnings with disappointing guidance.
So what: Revenue in the first quarter was $324.7 million, easily topping the Street's forecast of $317.1 million. The non-GAAP earnings per share of $0.45 was also well ahead of consensus estimates, which were calling for just $0.31 per share. The real cause for investor concern was conservative guidance.
Now what: Second-quarter outlook calls for revenue in the range of $342 million to $347 million, which is below consensus at $359.2 million. Adjusted EBITDA in the quarter should be $77 million to $79 million. Full-year sales are expected in the range of $1.43 billion to $1.46 billion, also short of expectations. LinkedIn grew its member base to 218 million.
Top Healthcare Technology Companies To Invest In Right Now: Euro/Yen(EJ)
E-House (China) Holdings Limited, through its subsidiaries, operates as a real estate services company in China. It provides primary real estate agency services, secondary real estate brokerage services, real estate information and consulting services, real estate advertising services, real estate promotional event services, real estate online services, and real estate investment fund management services. The company offers primary real estate agency services to real estate developers. Its secondary real estate brokerage services include offering advisory services on choices of properties; accompanying potential buyers on house viewing trips; drafting purchase contracts; negotiating price and other terms; and providing preliminary proof of title, as well as coordinating with the notary, the bank, and the title transfer agency. The company also provides real estate information services comprising data subscription services and data integration services; and real estate cons ulting services, including land acquisition consulting, development consulting, marketing consulting, and comprehensive solution consulting. In addition, it offers real estate advertising services consisting of advertising design and sales in print and other media; and real estate promotional event services, including securing venues, hiring caters and other various service providers, formulating event themes, and inviting speakers and guests for real estate promotional events. Further, the company provides real estate online services, including real estate news, information, property data, and access to online communities to real estate consumers and participants through local Web sites; and involves in real estate investment fund management activities that consist of investments in China?s real estate sector. E-House (China) Holdings Limited was founded in 2000 and is headquartered in Shanghai, the People?s Republic of China.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Wednesday morning, the financial sector proved to be a source of strength for the market. Leading the sector was strength from SouFun Holdings (NYSE: SFUN) and E-House (China) Holdings (NYSE: EJ). In trading on Wednesday, energy shares were relative laggards, down on the day by about 0.67 percent. Among the energy stocks, Endeavour International (NYSE: END)was down more than 22 percent, while TransGlobe Energy (NASDAQ: TGA) tumbled around 6 percent. - [By Richard Schmidt]
e-House Holdings Limited (EJ), a Chinese real estate services company, continued its move back up in November. With strong third-quarter earnings, the stock jumped up over 30%.
- [By Seth Jayson]
E-House (China) Holdings (NYSE: EJ ) reported earnings on May 16. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), E-House (China) Holdings crushed expectations on revenues and beat expectations on earnings per share. - [By Richard Schmidt]
Shares of e-House Holdings Limited (EJ) finally came to life in the last five months of last year. They cooled off in January, but moved back up in February.
Top Healthcare Technology Companies To Invest In Right Now: SilverCrest Mines Inc (SVLC)
SilverCrest Mines Inc. (SilverCrest), incorporated on May 22, 1973, is engaged in the acquisition, exploration and development of mineral properties in Mexico and Central America. The Company�� principal focus is the development and operation of the Santa Elena Project, which property consists of seven mineral concessions totaling 2,726.54 hectares, portions of which include the producing Santa Elena gold and silver mine located northeast of Hermosillo, Sonora State, Mexico. It operates in three segments: the mine operations at Santa Elena, Mexico; mine exploration and evaluation projects at La Joya and Cruz de Mayo, Mexico, and Corporate. The Company is also focused on exploring and developing its La Joya Property located in Durango, Mexico, which contains a discovered polymetallic deposit. The Company�� other mineral properties include the Cruz de Mayo Project (Mexico), the La Joya Property (Mexico), the Silver Angel Project (Mexico) and the El Zapote Project (El Salvador).
The La Joya Property consists of 14 mineral concessions with a total area of approximately 8,379.6 hectares. Its Cruz de Mayo Project consists of two mineral concessions comprising a total of 452 hectares. The Company holds a 100% interest in the Cruz de Mayo 2 concession (which encompasses 434 hectares). The Silver Angel Project consists of two mineral concessions encompassing a total of 3,251 hectares located in the northern Sierra Madre Range in Sonora, Mexico. The Company holds a 100% interest in these concessions, which were acquired by concession applications.
The El Zapote Project consists of two mineral concessions (the El Caliche and San Juan Exploration Concessions) located in the Department of Santa Ana in northern El Salvador, Central America. The Company holds a 100% interest in the El Zapote Project. During the year ended December 31, 2011, an initial drill program of 25 holes totaling approximately 2,900 meters was completed on the Santa Elena Norte target, located approximately 1 kilo! meters north of the Santa Elena Mine.
Advisors' Opinion:- [By Hebba Investments]
Even with rising Q2 costs, GG still has lower true all-in costs than many of its larger competitors' Q1FY13 costs. Compared to Q1FY13 numbers of competitors such as Yamana Gold (AUY) (costs just over $1300), Kinross Gold (KGC) (costs above $1350), Silvercrest Mines (SVLC) (costs below $1100), Newmont Gold (NEM) (costs around $1300) Agnico-Eagle (AEM) (costs around $1400) and Barrick Gold (ABX) (costs around $1200).
Hot Solar Companies To Buy Right Now: Kyocera Corp (KYOCF)
KYOCERA CORPORATION mainly develops products for the information and communications market. The Fine Ceramic segment offers semiconductor and liquid crystal manufacturing equipment parts, and information communication parts. The Semiconductor Parts segment offers ceramic and optical communication packages. The Fine Ceramic Applied Product Related segment offers residential, industrial photovoltaic generations. The Electronic Device segment offers ceramic capacitors, tantalum capacitors. The Communication Device segment provides personal handy phone systems (PHSs). The Information Equipment segment offers monochromes and combined machine. The Others segment provides information communication services. On April 1, 2013, it transferred the liquid crystal display related business to KYOCERA Display Corporation. On October 1, 2013, it acquired a 55% stake in NEC TOPPAN CIRCUIT SOLUTIONS, INC. from Toppan Printing Co Ltd, and acquired another 45% stake from NEC Corporation. Advisors' Opinion:- [By Daniel Inman]
Shares of Japanese real-estate companies managed to move higher in Tokyo, with Mitsui Fudosan (JP:8801) � (MTSFF) �up 1.6%, and Mitsubishi Estate Co. (JP:8802) � (MITEF) �up 1.9%. Local exporters, however, failed to lead the market lower: Honda Motor Co. (JP:7267) � (HMC) �lost 0.8%, and Kyocera Corp. (JP:6971) � (KYOCF) �fell 0.6%
- [By MARKETWATCH]
LOS ANGELES (MarketWatch) -- Japanese stocks weakened in early Thursday trading as the yen rose and Wall Street ended mixed, with the Nikkei Stock Average (JP:NIK) falling 1.2% to 15,929.74 after a 1.9% advance a day earlier. With the yen (USDJPY) slightly firmer than in the previous session, some investors sold currency-sensitive exporters, with Fanuc Corp. (JP:6954) (FANUF) down 2%, Kyocera Corp. (JP:6971) (KYOCF) off 1.9%, and Fujitsu Ltd. (JP:6702) (FJTSY) losing 2.3%. News that China would lift a ban on some sales of videogame consoles had sent shares of Nintendo Co. (JP:7974) (NTDOF) shooting 11% higher on Wednesday, but apparent profit-taking sent the stock down 4.2% in early Thursday action. Shares of rival Sony Corp. (JP:6758) (SNE) , however, followed with a 4% rise, also possibly buoyed by a Nikkei Asian Review report that it was planning a "smartphone offensive" in the U.S. and China. Canon Inc. (JP:7751) (CAJ) fell 2% on a separate Nikkei report that the company's 2013 operating profit would miss forecasts. Toshiba Corp. (JP:6502) (TOSYY)
Top Healthcare Technology Companies To Invest In Right Now: Cannabusiness Group Inc (CBGI)
Cannabusiness Group Inc, formerly Muscle Warfare International Inc, incorporated on June 24, 2005, focuses to research, evaluate, and acquire profitable private firms in the business segments of entertainment, technology, medical, energy, and business services for the benefit of its shareholders. The Company's subsidiaries include American West Baseball League and Elite Representation Associates. In April 2013, it announced acquiring 100% of Muscle Warfare, Inc. In July 2013, the Company announced the acquisition of a company that develops, manufactures, and markets sports nutrition products for athletes around the world in all sports, including both professional and amateur enthusiasts.
Elite Representation Associates is an athlete/coach management and marketing agency. The American West Baseball League is a professional, independent baseball organization located primarily in the Southwest United States. It operates in cities not served by major or minor league baseball team.
Advisors' Opinion:- [By Dan Burrows]
From questions regarding the accuracy of publicly-available information about these companies��operations to potential illegal activity, these marijuana stocks have incurred the wrath of federal regulators for good reason:
GrowLife (PHOT) FusionPharm (FSPM) CannaBusiness Group (CBGI) Advanced Cannabis Solutions (CANN) Petrotech Oil and Gas (PTOG) Marijuana Stocks Asking for TroubleBut it doesn’t end there. Investors should run away from all OTC marijuana stocks, including Medical Marijuana (MJNA), Cannabis Science (CBIS), CannaVest (CANV), MediSwipe (MWIP) and GreenGro Technologies (GRNH). As the SEC warns:
Top Healthcare Technology Companies To Invest In Right Now: Solazyme Inc (SZYM)
Solazyme, Inc. (Solazyme), incorporated on March 31, 2003, makes oil. The Company�� technology transforms a range of plant-based sugars into oils. Its renewable products can replace or enhance oils derived from the world�� three existing sources-petroleum, plants and animal fats. The Company is focused on commercializing its products into three target markets: fuels and chemicals, nutrition, and skin and personal care. In 2010, the Company launched its products, the Golden Chlorella line of dietary supplements. In March 2011, the Company launched its Algenist brand for the luxury skin care market through marketing and distribution arrangements with Sephora S.A. (Sephora International), Sephora USA, Inc. (Sephora USA), and QVC, Inc. (QVC).
The Company is engaged in development activities with multiple partners, including Chevron U.S.A. Inc., through its division Chevron Technology Ventures (Chevron), The Dow Chemical Company (Dow), Ecopetrol S.A. (Ecopetrol), Qantas Airways Limited (Qantas) and Conopoco, Inc., doing business as Unilever (Unilever).
In 2010, the Company entered into a 50/50 joint venture with Roquette Freres, S.A. (Roquette). In November 2010, the Company entered into a joint venture and operating agreement for Solazyme Roquette Nutritionals with Roquette. In December 2010, the Company entered into an exclusive distribution relationship with Sephora International, and in January 2011, the Company entered into a distribution relationship with Sephora USA. Under the arrangements, each of Sephora International and Sephora USA will distribute the Algenist product line in their respective territories.
In Fuels and Chemicals market its renewable oils can be refined and sold as drop-in replacements for marine, motor vehicle and jet fuels, as well as replacements for chemicals that are traditionally derived from petroleum or other conventional oils. The Company work with its refining partner Honeywell UOP to produce Soladiesel (renewable diesel), So! ladiesel renewable diesel for United States Naval vessels, and Solajet renewable jet fuel for both military and commercial application testing. In nutrition market the Company has developed microalgae-based food ingredients, including oils and powders that enhance the nutritional profile and functionality of food products while reducing costs for consumer packaged goods (CPG) companies. In Skin and Personal Care market the Company hs developed a portfolio of branded microalgae-based products. Its ingredient is Alguronic Acid, which the Company has formulated into a range of skin care products with anti-aging benefits. The Company is also developing algal oils as replacements for the oils used in skin and personal care products.
The Company competes with BP p.l.c., Royal Dutch Shell plc, and Exxon Mobil Corporation, jatropha, camelina, SALOV North America Corporation, Archer Daniels Midland Company, Cargill, Incorporated, DSM Food Specialties and Danisco A/S
Advisors' Opinion:- [By Travis Hoium]
What: Shares of Solazyme (NASDAQ: SZYM ) fell as much as 20% today after it agreed to dissolve a promising joint venture.
So what: Solazyme and Roquette, a starch and starch-derivatives company, agreed to dissolve a joint venture formed in 2010 to create alternative foods from microalgae. The companies couldn't decide on a manufacturing and marketing strategy so they decided to go their separate ways. �
- [By Maxx Chatsko]
Renewable-oils manufacturer Solazyme (NASDAQ: SZYM ) began supplying the U.S. Navy with Naval marine diesel and Naval jet fuel in 2010. In all, the company delivered nearly 1 million liters of fuel under various contracts between 2009 and 2012. The company took a lot of heat for the $15-per-gallon price tag for the contract -- nearly four times the price of conventional jet fuel at the time -- but critics seemed to have dismissed the fact that those selling prices included costs for new equipment and non-commercial scale inefficiencies.
- [By Maxx Chatsko]
Synthetic biology and renewable oils manufacturer�Solazyme� (NASDAQ: SZYM ) announced that it successfully conducted multiple initial fermentations in 500,000 liter fermentors in December 2012. While it was a big step forward in the right direction, I think the announcement was a bit premature. By "multiple," the company meant two and by "commercial scale production metrics," the company meant that only partial data had been collected. By reading SEC filings, investors can learn that the company has yet to prove microbial productivity at volumes greater than 128,000 liters. Not at all a nail in the coffin, but since the company believes it needs to reach 625,000 liter fermentors to be profitable, it is clear that engineers have plenty of work ahead of them.
- [By Robert Rapier]
There's a company called Solazyme (SZYM) who actually makes fuel out of algae; but they couldn't make it very economically so they shifted into neutroceuticals and pharmaceuticals and making oils for cosmetics and things like that.
Top Healthcare Technology Companies To Invest In Right Now: Vocus Inc.(VOCS)
Vocus, Inc. provides cloud marketing software that enables businesses attract, engage, and retain customers in the United States, Europe, Asia, and Morocco. It offers a suite of software for social media marketing, search marketing, email marketing, and publicity. The company?s cloud marketing solutions include search marketing and news distribution solution that helps customers increase their online visibility and organic search engine rankings with press releases; and email marketing solution, which provides a method of keeping in touch with prospects and customers by using professional looking emails to send newsletters, special offers, and other useful content. Its cloud marketing solutions also comprise social media software solution that helps customers run social marketing campaigns, as well as monitor and analyze conversations across multiple social networks and other online Websites; and publicity solution, which offers media database, news monitoring, and analyt ics and publicity opportunities that help companies increase their media exposure, manage relationships with reporters, and monitor and analyze trends unfolding in the media. The company also provides professional services that consist of data migration, custom development, and training. Vocus, Inc. sells its products to the financial and insurance, technology, healthcare and pharmaceutical, and retail and consumer products industries, as well as government agencies, not-for-profit organizations, and educational institutions through its direct sales channels, indirect sales channels, and the Internet. Vocus, Inc. was founded in 1988 and is headquartered in Beltsville, Maryland.
Advisors' Opinion:- [By Alex Planes]
What: Shares of Vocus (NASDAQ: VOCS ) have plunged 15% today after the company's forward guidance failed to impress the Street.
So what: Vocus reported its earnings last evening, and both the $46.6 million top line and the $0.01 earnings per share result were better than Wall Street's consensus, which sought a $45.3 million revenue number and a $0.02 loss per share. However, third-quarter guidance of $46.5 million to $46.8 million on the top line is below the $47 million consensus, and a $0.03 to $0.04 EPS result is roughly in line with the $0.03 consensus. Additionally, the full fiscal year's guidance of $188 million to $189 million is roughly in line with the $188.2 million consensus.
- [By Rich Smith]
In a separate statement, the company announced a small change in management, bringing in ex-Vocus (NASDAQ: VOCS ) Chief Operating Officer William R. Wagner to become its own COO. In an SEC filing, LogMeIn noted that it will pay Wagner $400,000 in annual base salary, plus:
- [By Seth Jayson]
Vocus (Nasdaq: VOCS ) reported earnings on April 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Vocus met expectations on revenues and missed estimates on earnings per share. - [By The GeoTeam]
Our recent 2013 articles on SaaS companies Selectica (SLTC), E2open (EOPN), Responsys (MKTG), Vocus (VOCS), and ExactTarget (ET) highlighted such opportunities. The average return since the inception of our coverage currently stands at around 34% (55% at their highs).
Top Healthcare Technology Companies To Invest In Right Now: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By RedChip]
Cancer Genetics (NASDAQ: CGIX), an emerging leader in DNA-based cancer diagnostics, priced a $15 million secondary offering and began trading on the NASDAQ today.
The offering will bring in a sizable cash infusion to CGIX, setting the stage for continued expansion of the Company�� sales and marketing efforts, as well as further product development and commercialization. In addition, it will enable the Company to fund its joint venture investment with Mayo Clinic and retire mezzanine financing. - [By RedChip]
Cancer Genetics, Inc. (NASDAQ: CGIX) had a big run in September; at one point, shares were up more than 130% over their IPO and secondary offering price of $10.
Top Healthcare Technology Companies To Invest In Right Now: Green Technology Solutions Inc (GTSO)
Green Technology Solutions Inc (GTSO), incorporated on February 22, 1991, is in the business of identifying and acquiring rights in early stage, green technologies, with the plan to develop these technologies into marketable products. The Company has identified several technology endeavors.
As of December 31, 2011, the Company has identified the advancement of mining technologies, with an emphasis on rare earth and precious metals mining applications, the development of additional markets for existing paint products that are being marketed in the United States, and smart grid technology. GTSO has also identified additional joint venture in China and South America.
Advisors' Opinion:- [By CRWE]
Today, GTSO has shed (-5.66%) down -0.0018 at $.0300 with�22,150 shares in play thus far (ref. google finance Delayed: 11:34AM EDT July 3, 2013), but don�� let this get you down.
Previously after forging a new joint venture, Green Technology Solutions, Inc. and Chilerecicla are already hard at work identifying new Latin American companies and locales ideally suited to the partnership�� ambitious expansion plans.
The partnership has targeted Latin America for expansion because it�� a key emerging market in the booming global e-waste recycling and reuse services industry, which Transparency Market Research predicts accounted for more than $9 billion in 2012. The firm expects the worldwide e-waste market to reach $18 billion in 2017, growing at a compound annual growth rate of 13.2 percent from 2012 to 2017.
- [By CRWE]
Today, GTSO surged (+13.33%) up +0.0040 at $.0340 with�43,370 shares in play thus far (ref. google finance Delayed: 12:18PM EDT September 20, 2013).
With heightened tensions in the Middle East expected to push oil prices to their highest levels in years, Green Technology Solutions, Inc. (OTCBB: GTSO) is aggressively looking into the more economical option of advanced biofuels.
A potential military strike by the United States against Syria is expected to elevate oil and gasoline prices to unprecedented heights. GTSO, an environmentally conscious company with an ongoing interest in delivering ��reen friendly��solutions to a global market, is exploring the option of comparatively inexpensive biofuels, assets that have the potential to figure prominently once again amidst current global chaos.
- [By CRWE]
Today, GTSO has shed (-10.51%) -0.0041 at $.0349 with 1,304,937 shares in play thus far (ref. google finance Delayed: 2:03PM EDT August 13, 2013).
Green Technology Solutions, Inc. and its partner, Chilerecicla, are preparing to expand recycling operations into Bolivia.
One of South America�� top recyclers of e-waste, Chilerecicla operates the first e-waste recycling plant in Southern Chile and maintains crucial relationships with overseas smelters, with the right to sell them as many recovered metals and minerals as GTSO and Chilerecicla can provide. With a feasibility study on the region now complete, the joint venture has targeted Bolivia as an ideal territory for growth.
Top Healthcare Technology Companies To Invest In Right Now: MicroStrategy Incorporated(MSTR)
MicroStrategy Incorporated provides enterprise software platforms for business intelligence (BI), and mobile and social intelligence applications worldwide. The company offers MicroStrategy 9, an integrated BI platform that enables businesses to make business decisions. The MicroStrategy 9 platform?s product components comprise Intelligence Server, a foundation for the BI platform; Report Services, a reporting engine delivering production and operational reports, managed metrics reports, and interactive dashboards; OLAP Services that allows Web and desktop users to manipulate Intelligent Cubes databases; Web, a Web interface providing query, reporting, and analysis; Distribution Services that offers automated report and dashboard distribution; Office, which enables Microsoft Office users to create, run, edit, and format MicroStrategy report; and Desktop that provide users access to data through analytical applications. The MicroStrategy 9 platform?s product components al so include Architect, whose data sources are modeled through an intuitive graphical user interface; SDK to integrate MicroStrategy 9 features and functionality into any application on multiple platforms; Integrity Manager to compare and verify reports? consistency; Command Manager that automates MicroStrategy administrative tasks; Enterprise Manager to provide prebuilt reports and dashboards; Object Manager that allows administrators to manage disparate and distributed environments; MultiSource Option allowing users to report, analyze, and monitor data; Transaction Services that provides write-back capabilities; and Clustering Option, a plug-and-play add-on to Intelligence Server. The company also offers technical support, consulting, education, and cloud-based solutions. It serves retail, communications, financial services, insurance, healthcare, manufacturing, technology, consumer goods, and public services industries. The company was founded in 1989 and is headquartered in Tysons Corner, Virginia.
Advisors' Opinion:- [By Tim Beyers and Erin Miller]
Importantly, the BI sector as a whole isn't seeing gains. MicroStrategy (NASDAQ: MSTR ) fell as much as Qlik gained on a 6% decline in revenues in the most recent quarter. Qlik, by contrast, reported a 22% rise in revenue and told analysts to expect another 20% or better bump in the quarter.
- [By John Udovich]
Yesterday, small cap business intelligence stock MicroStrategy Incorporated (NASDAQ: MSTR) surged 18.44%�after reporting better-than-expected third quarter earnings ��meaning it might be a good idea to take a closer look at it�along with�small cap peers Actuate Corporation (NASDAQ: BIRT) and Qlik Technologies Inc (NASDAQ: QLIK) to see what they might offer small cap investors. After all, everyone is being inundated with huge amounts of data from multiple sources, but its the following small cap stocks that provide software platforms to help customers try to make sense of it all:�
No comments:
Post a Comment